Insulet (PODD) Expected to Announce Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $1.48 per share and revenue of $768.3080 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Insulet Stock Up 0.8%

Shares of NASDAQ:PODD opened at $242.74 on Tuesday. Insulet has a 52-week low of $230.05 and a 52-week high of $354.88. The company has a market capitalization of $17.08 billion, a PE ratio of 70.36, a price-to-earnings-growth ratio of 1.37 and a beta of 1.41. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The company has a fifty day moving average of $276.12 and a 200-day moving average of $306.11.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Zacks Research downgraded Insulet from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Truist Financial lowered their price objective on Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Sanford C. Bernstein cut their target price on shares of Insulet from $410.00 to $380.00 and set an “outperform” rating on the stock in a research report on Friday, January 9th. BTIG Research boosted their target price on shares of Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a report on Friday, November 21st. Finally, Barclays raised their price target on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Twenty equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $374.10.

Institutional Trading of Insulet

A number of institutional investors have recently bought and sold shares of the company. State Street Corp grew its holdings in Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Insulet by 3.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after purchasing an additional 29,690 shares in the last quarter. Federated Hermes Inc. grew its stake in Insulet by 9.6% during the fourth quarter. Federated Hermes Inc. now owns 767,834 shares of the medical instruments supplier’s stock worth $218,249,000 after purchasing an additional 67,210 shares during the period. Northern Trust Corp grew its stake in Insulet by 0.5% during the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock worth $218,945,000 after purchasing an additional 3,618 shares during the period. Finally, Qube Research & Technologies Ltd increased its holdings in Insulet by 37.3% in the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock worth $177,324,000 after purchasing an additional 156,009 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.